News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Revolutionary technology will further boost OneSource’s scientific services offerings
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Additional capacity broadens Grace’s fine chemical capabilities for API production
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Subscribe To Our Newsletter & Stay Updated
